PR Newswire
25 May 2023, 06:40 GMT+10
Paradigm Biopharma launches clinical trial website to support development program for knee osteoarthritis therapy.
MELBOURNE, Australia, May 25, 2023 /PRNewswire/ -- With the launch of a new website dedicated to their global clinical trials (https://hope4OA.com), Paradigm Biopharmaceuticals Ltd. (Paradigm Biopharma) aims to provide relief to millions of osteoarthritis (OA) sufferers worldwide by developing a new injectable drug.
Almost one in seven American adults has osteoarthritis
OA is a progressive degenerative disease affecting millions worldwide, with estimates reaching nearly half a billion sufferers. Due to their weight bearing role, 70% of all cases affect the hip or the knee.
Ex-Australian Football League (AFL) player Greg 'Diesel' Williams understands all too well how knee OA can have a devastating impact on your life. Greg explains "If you've got OA people really don't understand what we're going through. It's so painful. It's so sore. It's so, so hard to put up with. And it's about time we did something about it."
Dr Philip Bloom is a specialist sports physician with over 20 years' experience and specialist training in treating and managing musculoskeletal injuries and diseases to maximise function. Dr Bloom explains "We see many ex-athletes who have developed osteoarthritis of the knee. They've gone from being super performers to barely being able to go for a decent walk with their family, and it has quite a disabling effect on their whole life."
Paradigm shift for OA treatments
People with OA need alternative therapeutic solutions, as current therapies often don't provide sufficient relief, leaving people in pain and reducing their quality of life.
Dr Philip Bloom comments "Osteoarthritis of the knee is not just an isolated pain in the knee. It has a trickle-down effect on the rest of your life, particularly in regards to losing the ability to be active, which causes obesity, more aches and pains in other joints, and also psychological problems such as depression and anxiety."
Despite the huge need for effective treatments, there are still no registered treatments that can successfully stop or even slow the disease.
Paradigm Biopharma aims to provide hope to OA sufferers by developing a drug to help relieve pain and improve symptoms in people with knee OA.
This drug has been used to treat joint issues in the veterinary space for over 80 years and is registered for use by veterinarians in over 20 countries to treat arthritis in cats, dogs, horses, and even racing camels.
To facilitate current and potential trial participants, Paradigm has launched a new trial website called Hope4OA.com.
Here everyone can discover trial details and find answers to commonly asked questions. If interested, they are invited to complete an online questionnaire to determine their eligibility as a potential trial participant.
The new site hosts helpful explanations and instructional videos on clinical trials as well as providing links to patient support and further information.
To find out more, go to www.hope4oa.com
About Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm's current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).
Get a daily dose of Malaysia Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Malaysia Sun.
More InformationBANGKOK, Thailand: Thailand's government is facing its biggest crisis in nearly a year, as Prime Minister Paetongtarn Shinawatra's...
Kolkata (West Bengal) [India], June 26 (ANI): The leader of the Opposition in the West Bengal Assembly and BJP leader Suvendu Adhikari...
Patna (Bihar) [India], June 26 (ANI): Bihar Deputy Chief Minister Samrat Choudhary on Wednesday lashed out at the Congress party on...
New Delhi [India], June 26 (ANI): BlueKraft Digital Foundation has published a book, 'The Emergency Diaries: Years that Forged a Leader'....
Kathmandu [Nepal], June 26 (ANI): A Special Court in Nepal has ordered the release of former Nepali Prime Minister Madhav Kumar Nepal...
Aizawl (Mizoram) [India], June 26 (ANI): Mizoram Chief Minister Lalduhoma on Wednesday chaired an online meeting of the High Level...
NEW YORK, New York, - U.S. stocks were split, but little moved Wednesday after a positive start to the week heralded by a two-day rally....
NEW YORK CITY, New York: Elon Musk is taking a big step toward making his long-promised robotaxi dream a reality. Over the weekend,...
PLANO, Texas: Toyota Motor will raise prices across a range of vehicles in the United States starting next month, the Japanese automaker...
WASHINGTON, D.C.: U.S. business activity showed signs of softening in June while inflationary pressures continued to build, driven...
NEW YORK, New York - U.S. stock markest closed sharply higher on Tuesday as a truce entered into between Irsael and Iran after 12 days...
MENLO PARK, California: Meta is taking another swing at smart eyewear—this time with a sporty edge. The company announced a new partnership...